U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.

DBV Technologies’ Phase III peanut allergy trial failed to show a statistically significant response against placebo.

Aimmune Therapeutics said on Monday it would collaborate with Regeneron Pharmaceuticals and Sanofi to develop its experimental peanut allergy drug.

HERSHEY, Pa. and ROCKVILLE, Md. and TOKYO, Oct. 9, 2015 /PRNewswire/ — Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. (“Astellas”) today announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any […]